All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Featured:
The Lymphoma Hub Satellite Symposium at 15-ICML brought together an international panel of experts to discuss the novel chemotherapy-free treatment approaches for lymphoid malignancies. Professor Nathan Fowler, University of Texas MD Anderson Cancer Centre, Houston, US, presented the current state of play with FL chemotherapy-free treatments.
Lymphoma Hub Satellite Symposium 2019 - Professor Nathan Fowler
Professor Fowler demonstrated that long-term survival rates have more than doubled in the last 50 years with improvements in chemotherapy regimens and the addition of rituximab. He also highlighted the influx of newer treatments in recent years (such as antibodies, PI3K inhibitors, and immunomodulatory treatments) with little known long-term outcomes.
Prof. Fowler went on to discuss the distinctive tumor microenvironment and related immune dysfunction associated with FL which contribute to the promotion of tumor cell survival and proliferation. Therapeutics such as rituximab and lenalidomide can be used to exploit these altered mechanisms. Although many patients benefit from chemotherapy, the treatment is associated with side effects, including fatigue, nausea, cytopenia, and even secondary malignancies. As many patients are not cured, Prof. Fowler emphasized the need for alternative chemotherapy-free treatment regimens.
He went on to discuss PI3K inhibitors, the similarity in terms of ORR (40-60%) and median PFS at around 11 months, and slight differences in their toxicity profile. All PI3K inhibitors appear to induce neutropenia, diarrhea, nausea, fatigue, and coughing at varying degrees. He then discussed the R2 combination treatment (lenalidomide and rituximab) presenting the RELEVANCE and AUGMENT trial data.
The RELEVANCE trial assessed R2 as a front-line treatment and demonstrated similar efficacy to chemotherapy, but with different side effects (cutaneous reactions and rashes with R2, more febrile neutropenia with chemotherapy). The AUGMENT trial assessed R2 as a treatment in R/R FL and found it to convey better ORR and PFS rates also in high-risk patients when compared to rituximab alone, yet with higher toxicity.
Prof. Fowler said he would treat most patients with R2 unless there were signs of transformation. In terms of post-treatment transformation, he had seen very few R2 treated patients with transformation at 5 years follow up. He brought his presentation to a close with some preliminary data on tazemetostat and CTL109, a CAR T-cell product.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?